Opinion
New weight loss drugs raise questions of access, costs
New, popular injectable weight loss drugs — GLP-1 drugs — are highly effective at reducing obesity and, probably, the health risks posed by obesity. Yet the drugs are so expensive that insurers are often choosing between two bad options: restricting access or raising consumer costs.
10don MSN
Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...
Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., ...
which later won FDA approval for weight loss in 2023 under the brand name Zepbound. A similar version of this drug, called Mounjaro, has been available to people with type 2 diabetes since ...
Maez Waibel lost more than 30 pounds in nine months on the new weight-loss drugs, sparking a substantial improvement in health. But instead of feeling happy and relieved, Waibel’s days have ...
The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback